scholarly journals Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report

Immunotherapy ◽  
2021 ◽  
Author(s):  
Lei Song ◽  
Rengui Zhou ◽  
Xiangyong Li ◽  
Dejian Pan
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
The Third ◽  
Third Line

Small-cell lung cancer (SCLC) is sensitive to chemoradiotherapy but remains to have a poor prognosis. In the immunotherapy era, chemotherapy combined with PD-L1 inhibitors has become a new first-line treatment option for advanced SCLC. The CheckMate 032 study combined a PD-1 blockade and a CTLA-4 inhibitor and found that this dual immunotherapy might be a positive treatment choice for SCLC. In our case, the patient with advanced SCLC received bevacizumab combined with dual immunotherapy over the third line with more than 12 months survival time. The overall survival time was 21.5 months from the start of the third-line treatment and 39 months from the time of extensive-disease SCLC diagnosis. The combination of a VEGF blockade and a dual immunotherapy in SCLC resulted in synergistic treatment effects. Therefore, bevacizumab might be a better adjuvant, either combined with chemotherapy or dual immunotherapy, for patients with persistent disease progression after undergoing immunotherapy.

scholarly journals Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

2021 ◽  
pp. 1-1
Author(s):  
Caitlin Smare ◽  
Kiran Dave ◽  
Ariadna Juarez-Garcia ◽  
Pranav Abraham ◽  
John R. Penrod ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

scholarly journals Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience

2021 ◽  
Vol 20 ◽  
pp. 153303382110507
Author(s):  
Yuchao Wang ◽  
Li Li ◽  
Chunhua Xu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adverse Reactions ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

Background: Small cell lung cancer (SCLC) is a type of highly malignant tumor. It is easy to relapse and high resistant to second-line chemotherapy. There is not a standard plan for third-line and subsequent-line treatment, hence the current study aimed to explore the performance of nanoparticle albumin bound paclitaxel (Nab-P) in the third-line treatment of recurrent SCLC. Methods: A retrospective analysis of pathologically confirmed third-line SCLC patients was conducted to observe the efficacy and adverse reactions of Nab-P treatment. Results: Among the 37 SCLC patients included in the study, objective response rate was 24.32%, and disease control rate was 81.08%. The main adverse reactions were gastrointestinal reactions, bone marrow suppression, muscle and joint aches and fatigue. Adverse reactions ≥ level 3 included leukopenia & neutropenia (24.32%), thrombocytopenia (5.41%) and anemia (2.70%). Conclusions: As a single-agent third-line treatment for patients with relapsed SCLC, Nab-P was effective and safe.

Second and third line treatment in non-small cell lung cancer

2009 ◽  
Vol 71 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Adolfo Favaretto ◽  
Giulia Pasello ◽  
Cristina Magro ◽  
Clorinda Schettino ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment

scholarly journals P1-215: Three drug regiment (Irinotecan, Carboplatin and Etoposide) as a front line treatment in extensive disease small-cell lung cancer: phase II trial

2007 ◽  
Vol 2 (8) ◽  
pp. S824
Author(s):  
Andriani G. Charpidou ◽  
Nikolaos Katirtzoglou ◽  
Ioannis Gkiozos ◽  
Eleni Karapanagiotou ◽  
Anna Rigopoulou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Line Treatment ◽  
Front Line ◽  
Small Cell Lung ◽  
Extensive Disease

scholarly journals The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

2021 ◽  
Vol 10 ◽  
Author(s):  
Chongya Zhai ◽  
Xiaoling Zhang ◽  
Lulu Ren ◽  
Liangkun You ◽  
Qin Pan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
The Common ◽  
Third Line

BackgroundBoth anlotinib and programmed death 1 (PD-1) monoclonal antibody (mAb) have been approved for the third line treatment of metastatic non-small cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.MethodsWe reviewed 22 patients with NSCLC who received anlotinib combined with PD-1 mAb therapy from July 2018 to October 2019 at Sir Run Run Shaw Hospital. Based on the baseline characteristics, PD-L1 expression and EGFR mutation status, we retrospectively analyzed the efficacy and safety of this combination therapy by RESIST 1.1 and CTCAE 5.0.ResultsThe combination treatment of anlotinib and PD-1 mAb in 22 NSCLC patients gained a median PFS of 6.8 months and a median OS of 17.3 months. The disease control rate (DCR) was 90.9%, and the objective response rate (ORR) was 36.4%, where 1 (4.6%) patient achieved complete response (CR) and 7 (31.8%) patients achieved partial response (PR). The median time to response was 3.9 months, and the median duration of the response was 6.8 months. The common grades 1–2 adverse events were fatigue 10/22 (45.5%), decreased appetite 9/22 (40.9%), hypertension 10/22 (45.5%); the common grades 3–4 adverse events were hypertension 2/22 (9.1%) and mouth ulceration 2/22 (9.1%).ConclusionAnlotinib combined with PD-1 mAb showed promising efficacy in third-line or further-line treatment of NSCLC, and its adverse effects is tolerable.

Sign in / Sign up

Export Citation Format

Share Document